Tumors evade immune detection by downregulating antigen presentation and hindering immune responses. Type 1 conventional dendritic cells (cDC1s) are vital in stimulating cytotoxic T cells against tumors. Ascic et al. are now demonstrating the in situ ability of PU.1, IRF8, and BATF3 (PIB) transcription factors to directly reprogram a plethora of tumors bypassing the suppressive effects of the tumor microenvironment, and leading to overall tumor regression while eliciting a systemic immune response that can protect from secondary tumor induction.
Get full access to this article
View all access options for this article.
References
1.
AscicE, ÅkerströmF, Sreekumar NairM, et al.In vivo dendritic cell reprogramming for cancer immunotherapy. Science, 2024:eadn9083.
2.
FerreiraAG, ZimmermannovaO, KurochkinI, et al.Reprogramming cancer cells to antigen-presenting cells. Bio Protoc, 2023; 13(22):e4881.
3.
RosaFF, PiresCF, KurochkinI, et al.Direct reprogramming of fibroblasts into antigen-presenting dendritic cells. Sci Immunol, 2018; 3(30).
4.
RosaFF, PiresCF, KurochkinI, et al.Single-cell transcriptional profiling informs efficient reprogramming of human somatic cells to cross-presenting dendritic cells. Sci Immunol, 2022; 7(69):eabg5539.
5.
YadavM, DelamarreL. Immunotherapy. Outsourcing the immune response to cancer. Science, 2016; 352(6291):1275–1276.
6.
ZimmermannovaO, FerreiraAG, AscicE, et al.Restoring tumor immunogenicity with dendritic cell reprogramming. Sci Immunol, 2023; 8(85):eadd4817.
